Dr. Christopher G. Bunick, M.D., PH.D.
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- Medical school
- Vanderbilt University School of Medicine (2008)
- Years since graduation
- 18
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 595
Licensed in Connecticut since 2012, according to the Connecticut Department of Public Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Medical school: Vanderbilt University School of Medicine
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
CT license 50906 (first issued 2012; active in renewal) - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Yale-New Haven Hospital New Haven, CT
- Saint Mary's Hospital Waterbury, CT
- Waterbury Hospital Waterbury, CT
Medical groups
- Yale University (2,645 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 595
- Services billed
- 1,945
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 554 | 115 |
| Established patient office or other outpatient visit, 20-29 minutes | 491 | 412 |
| Destruction of precancer skin growth, 1 growth | 192 | 169 |
| Biopsy of related skin growth, first growth | 161 | 138 |
| Destruction of skin growth, 1-14 growths | 95 | 87 |
| Biopsy of related skin growth, each additional growth | 83 | 47 |
| New patient office or other outpatient visit, 30-44 minutes | 67 | 67 |
| Established patient office or other outpatient visit, 30-39 minutes | 38 | 34 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 35 | 29 |
| Established patient office or other outpatient visit, 10-19 minutes | 25 | 25 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Clobetasol Propionate Other prescribers in New Haven, CT | 212 |
| Triamcinolone Acetonide Other prescribers in New Haven, CT | 193 |
| Ketoconazole Other prescribers in New Haven, CT | 141 |
| Dupixent Pen (dupilumab) Other prescribers in New Haven, CT | 105 |
| Dupixent Syringe (dupilumab) Other prescribers in New Haven, CT | 68 |
| Doxycycline Hyclate Other prescribers in New Haven, CT | 60 |
| Metronidazole Other prescribers in New Haven, CT | 43 |
| Minoxidil Other prescribers in New Haven, CT | 42 |
| Skyrizi Pen (risankizumab-rzaa) | 41 |
| Tretinoin | 35 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 20 companies reported 256 payments worth $238,787 in total to this clinician.
| Leo Pharma Inc. | $41,180 |
|---|---|
| Pfizer Inc. | $33,943 |
| Takeda Pharmaceuticals U.S.A., Inc. | $32,681 |
| Novartis Pharmaceuticals Corporation | $25,506 |
| UCB, Inc. | $19,745 |
| AbbVie Inc. | $16,299 |
| Genzyme Corporation | $13,413 |
| Incyte Corporation | $13,313 |
| Consulting Fee | $213,138 |
|---|---|
| Travel and Lodging | $11,227 |
| Food and Beverage | $8,120 |
| Compensation for services other than consulting (speaking, faculty) | $6,133 |
| Education | $169 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. Apr 29, 2025 | Consulting Fee | $12,768 |
| Genzyme Corporation Nov 8, 2025 | Consulting Fee DUPIXENT · Immunology | $9,757 |
| Pfizer Inc. May 22, 2025 | Consulting Fee LITFULO · IMMUNOLOGY | $9,320 |
| UCB, Inc. Aug 19, 2025 | Consulting Fee Bimzelx · Immunology | $9,000 |
| Novartis Pharmaceuticals Corporation May 2, 2025 | Consulting Fee | $8,000 |
| Novartis Pharmaceuticals Corporation Aug 16, 2025 | Consulting Fee | $7,750 |
| AbbVie Inc. Dec 10, 2025 | Consulting Fee RINVOQ · IMMUNOLOGY | $6,400 |
| Eli Lilly and Company Jul 23, 2025 | Consulting Fee EBGLYSS · Immunology | $5,600 |
| Takeda Pharmaceuticals U.S.A., Inc. Nov 20, 2025 | Consulting Fee | $5,187 |
| Sun Pharmaceutical Industries Inc. Oct 24, 2025 | Consulting Fee ILUMYA · Dermatology | $5,000 |
All 118 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Dec 22, 2025 | Consulting Fee CIBINQO · Inflammation & Immunology | $2,980 |
| Pfizer Inc. Dec 22, 2025 | Consulting Fee CIBINQO · Inflammation & Immunology | $1,490 |
| Leo Pharma Inc. Dec 18, 2025 | Consulting Fee ADBRY; ANZUPGO · DERMATOLOGY | $2,263 |
| Galderma Laboratories, L.P. Dec 17, 2025 | Consulting Fee NEMLUVIO · DERMATITIS | $4,000 |
| AbbVie Inc. Dec 10, 2025 | Consulting Fee RINVOQ · IMMUNOLOGY | $6,400 |
| AbbVie Inc. Dec 10, 2025 | Travel and Lodging RINVOQ · IMMUNOLOGY · travel to NEW HAVEN, CT · in-kind | $39.25 |
| AbbVie Inc. Dec 10, 2025 | Travel and Lodging RINVOQ · IMMUNOLOGY · travel to NEW HAVEN, CT · in-kind | $25.20 |
| Almirall LLC Nov 24, 2025 | Consulting Fee Klisyri; Seysara · Dermatology | $2,975 |
| Takeda Pharmaceuticals U.S.A., Inc. Nov 20, 2025 | Consulting Fee | $5,187 |
| Leo Pharma Inc. Nov 20, 2025 | Consulting Fee ADBRY; ANZUPGO · DERMATOLOGY | $2,263 |
| AbbVie Inc. Nov 15, 2025 | Travel and Lodging RINVOQ · IMMUNOLOGY · travel to NEW YORK, NY · in-kind | $253 |
| AbbVie Inc. Nov 15, 2025 | Travel and Lodging RINVOQ · IMMUNOLOGY · travel to NEW YORK, NY · in-kind | $85.00 |
| Genzyme Corporation Nov 8, 2025 | Consulting Fee DUPIXENT · Immunology | $9,757 |
| Genzyme Corporation Nov 8, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to Coral Gables, FL · in-kind | $433 |
| Genzyme Corporation Nov 8, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to Coral Gables, FL · in-kind | $315 |
| Leo Pharma As Nov 5, 2025 | Consulting Fee ADBRY · DERMATOLOGY | $2,670 |
| Novartis Pharmaceuticals Corporation Nov 3, 2025 | Consulting Fee | $3,750 |
| Sun Pharmaceutical Industries Inc. Oct 24, 2025 | Consulting Fee ILUMYA · Dermatology | $5,000 |
| Pfizer Inc. Oct 22, 2025 | Compensation for services other than consulting (speaking, faculty) | $134 |
| Pfizer Inc. Oct 22, 2025 | Compensation for services other than consulting (speaking, faculty) | $89.12 |
| AbbVie Inc. Oct 20, 2025 | Consulting Fee | $3,200 |
| AbbVie Inc. Oct 9, 2025 | Consulting Fee RINVOQ · IMMUNOLOGY | $800 |
| AbbVie Inc. Oct 9, 2025 | Consulting Fee SKYRIZI · IMMUNOLOGY | $800 |
| Pfizer Inc. Oct 8, 2025 | Consulting Fee | $3,576 |
| Pfizer Inc. Oct 8, 2025 | Consulting Fee | $2,384 |
| Sun Pharmaceutical Industries Inc. Oct 6, 2025 | Consulting Fee ILUMYA · Dermatology | $3,400 |
| Novartis Pharmaceuticals Corporation Oct 2, 2025 | Consulting Fee | $3,000 |
| Pfizer Inc. Sep 26, 2025 | Travel and Lodging travel to New York, NY · in-kind | $529 |
| Pfizer Inc. Sep 26, 2025 | Travel and Lodging travel to New York, NY · in-kind | $399 |
| Pfizer Inc. Sep 26, 2025 | Travel and Lodging travel to New York, NY · in-kind | $148 |
| Pfizer Inc. Sep 25, 2025 | Consulting Fee | $1,863 |
| Leo Pharma Inc. Sep 21, 2025 | Education in-kind | $125 |
| AbbVie Inc. Sep 17, 2025 | Consulting Fee | $800 |
| Arcutis Biotherapeutics, Inc. Sep 11, 2025 | Consulting Fee Zoryve · Dermatology | $1,500 |
| Leo Pharma Inc. Sep 8, 2025 | Consulting Fee | $2,680 |
| Takeda Pharmaceuticals U.S.A., Inc. Sep 3, 2025 | Consulting Fee | $1,596 |
| Pfizer Inc. Sep 2, 2025 | Consulting Fee | $2,235 |
| Sun Pharmaceutical Industries Inc. Aug 29, 2025 | Consulting Fee ILUMYA · Dermatology | $3,400 |
| Leo Pharma Inc. Aug 26, 2025 | Education in-kind | $25.00 |
| Eli Lilly and Company Aug 20, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,400 |
| UCB, Inc. Aug 19, 2025 | Consulting Fee Bimzelx · Immunology | $9,000 |
| UCB, Inc. Aug 19, 2025 | Travel and Lodging Bimzelx · Immunology · travel to Smyrna, GA | $376 |
| UCB, Inc. Aug 19, 2025 | Travel and Lodging Bimzelx · Immunology · travel to Smyrna, GA · in-kind | $74.40 |
| Novartis Pharmaceuticals Corporation Aug 16, 2025 | Consulting Fee | $7,750 |
| Novartis Pharmaceuticals Corporation Aug 16, 2025 | Travel and Lodging travel to ATLANTA, GA | $286 |
| Novartis Pharmaceuticals Corporation Aug 16, 2025 | Travel and Lodging travel to ATLANTA, GA · in-kind | $167 |
| AbbVie Inc. Aug 15, 2025 | Consulting Fee RINVOQ · IMMUNOLOGY | $800 |
| Novartis Pharmaceuticals Corporation Aug 15, 2025 | Travel and Lodging travel to Atlanta, GA · in-kind | $529 |
| Incyte Corporation Aug 8, 2025 | Consulting Fee OPZELURA · Dermatology | $4,875 |
| Incyte Corporation Aug 8, 2025 | Consulting Fee OPZELURA · Dermatology | $3,000 |
| UCB, Inc. Aug 1, 2025 | Travel and Lodging Bimzelx · Immunology · travel to Smyrna, GA · in-kind | $1,219 |
| UCB, Inc. Aug 1, 2025 | Travel and Lodging Bimzelx · Immunology · travel to Smyrna, GA · in-kind | $497 |
| UCB, Inc. Aug 1, 2025 | Travel and Lodging Bimzelx · Immunology · travel to Smyrna, GA · in-kind | $401 |
| UCB, Inc. Aug 1, 2025 | Travel and Lodging Bimzelx · Immunology · travel to Smyrna, GA · in-kind | $369 |
| UCB, Inc. Aug 1, 2025 | Travel and Lodging Bimzelx · Immunology · travel to Smyrna, GA · in-kind | $329 |
| UCB, Inc. Aug 1, 2025 | Travel and Lodging Bimzelx · Immunology · travel to Smyrna, GA · in-kind | $130 |
| UCB, Inc. Aug 1, 2025 | Travel and Lodging Bimzelx · Immunology · travel to Smyrna, GA · in-kind | $130 |
| UCB, Inc. Aug 1, 2025 | Travel and Lodging Bimzelx · Immunology · travel to Smyrna, GA · in-kind | $125 |
| UCB, Inc. Aug 1, 2025 | Travel and Lodging Bimzelx · Immunology · travel to Smyrna, GA · in-kind | $65.00 |
| UCB, Inc. Aug 1, 2025 | Travel and Lodging Bimzelx · Immunology · travel to Smyrna, GA · in-kind | $37.25 |
| Eli Lilly and Company Jul 25, 2025 | Travel and Lodging EBGLYSS · Immunology · travel to HAPEVILLE, GA | $57.40 |
| Eli Lilly and Company Jul 25, 2025 | Travel and Lodging EBGLYSS · Immunology · travel to HAPEVILLE, GA | $21.00 |
| Eli Lilly and Company Jul 23, 2025 | Consulting Fee EBGLYSS · Immunology | $5,600 |
| Eli Lilly and Company Jul 23, 2025 | Consulting Fee EBGLYSS · Immunology | $2,800 |
| Leo Pharma Inc. Jul 21, 2025 | Consulting Fee ANZUPGO · DERMATOLOGY | $3,846 |
| Takeda Pharmaceuticals U.S.A., Inc. Jul 18, 2025 | Consulting Fee | $1,596 |
| Incyte Corporation Jul 10, 2025 | Consulting Fee | $2,250 |
| Pfizer Inc. Jul 8, 2025 | Consulting Fee LITFULO · IMMUNOLOGY | $1,863 |
| AbbVie Inc. Jun 26, 2025 | Consulting Fee RINVOQ · IMMUNOLOGY | $800 |
| Incyte Corporation Jun 25, 2025 | Travel and Lodging OPZELURA · Dermatology · travel to Wilmington, DE | $386 |
| Incyte Corporation Jun 25, 2025 | Travel and Lodging OPZELURA · Dermatology · travel to Wilmington, DE | $369 |
| Leo Pharma Inc. Jun 18, 2025 | Consulting Fee ANZUPGO; ADBRY · DERMATOLOGY | $2,715 |
| Incyte Corporation Jun 17, 2025 | Consulting Fee OPZELURA · Dermatology | $2,250 |
| Pfizer Inc. Jun 17, 2025 | Compensation for services other than consulting (speaking, faculty) LITFULO · IMMUNOLOGY | $148 |
| Galderma Laboratories, L.P. Jun 4, 2025 | Consulting Fee NEMLUVIO · DERMATITIS | $1,600 |
| Pfizer Inc. May 22, 2025 | Consulting Fee LITFULO · IMMUNOLOGY | $9,320 |
| Leo Pharma Inc. May 20, 2025 | Consulting Fee ANZUPGO · DERMATOLOGY | $1,810 |
| Leo Pharma Inc. May 20, 2025 | Consulting Fee | $905 |
| Arcutis Biotherapeutics, Inc. May 8, 2025 | Consulting Fee Zoryve · Dermatology | $750 |
| Leo Pharma Inc. May 5, 2025 | Consulting Fee | $3,620 |
| Novartis Pharmaceuticals Corporation May 2, 2025 | Consulting Fee | $8,000 |
| Pfizer Inc. May 2, 2025 | Consulting Fee | $1,118 |
| Novartis Pharmaceuticals Corporation May 2, 2025 | Travel and Lodging travel to EAST HANOVER, NJ | $1,063 |
| Pfizer Inc. May 2, 2025 | Consulting Fee | $745 |
| Novartis Pharmaceuticals Corporation May 2, 2025 | Travel and Lodging travel to EAST HANOVER, NJ · in-kind | $228 |
| Novartis Pharmaceuticals Corporation May 1, 2025 | Education in-kind | $19.31 |
| Takeda Pharmaceuticals U.S.A., Inc. Apr 29, 2025 | Consulting Fee | $12,768 |
| Leo Pharma Inc. Apr 29, 2025 | Consulting Fee | $4,450 |
| Leo Pharma Inc. Apr 29, 2025 | Consulting Fee ANZUPGO · DERMATOLOGY | $2,715 |
| Takeda Pharmaceuticals U.S.A., Inc. Apr 29, 2025 | Travel and Lodging travel to CAMBRIDGE, MA · in-kind | $49.98 |
| Arcutis Biotherapeutics, Inc. Apr 8, 2025 | Consulting Fee Zoryve · Dermatology | $2,250 |
| Leo Pharma Inc. Apr 3, 2025 | Consulting Fee ANZUPGO; ADBRY · DERMATOLOGY | $2,263 |
| Takeda Pharmaceuticals U.S.A., Inc. Apr 3, 2025 | Consulting Fee | $2,195 |
| Takeda Pharmaceuticals U.S.A., Inc. Apr 2, 2025 | Consulting Fee | $4,788 |
| UCB, Inc. Apr 2, 2025 | Consulting Fee | $750 |
| UCB, Inc. Apr 2, 2025 | Consulting Fee | $750 |
| UCB, Inc. Apr 2, 2025 | Consulting Fee | $750 |
| UCB, Inc. Apr 2, 2025 | Consulting Fee | $375 |
| UCB, Inc. Apr 2, 2025 | Consulting Fee | $375 |
| Takeda Pharmaceuticals U.S.A., Inc. Apr 2, 2025 | Travel and Lodging travel to ORLANDO, FL · in-kind | $286 |
| Pfizer Inc. Mar 31, 2025 | Consulting Fee | $1,490 |
| AbbVie Inc. Mar 25, 2025 | Consulting Fee SKYRIZI · IMMUNOLOGY | $800 |
| AbbVie Inc. Mar 25, 2025 | Consulting Fee RINVOQ · IMMUNOLOGY | $800 |
| Genzyme Corporation Mar 9, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,563 |
| Almirall LLC Mar 6, 2025 | Compensation for services other than consulting (speaking, faculty) | $800 |
| Leo Pharma Inc. Mar 5, 2025 | Consulting Fee | $1,810 |
| Takeda Pharmaceuticals U.S.A., Inc. Feb 28, 2025 | Consulting Fee | $975 |
| Leo Pharma Inc. Feb 6, 2025 | Consulting Fee ADBRY · DERMATOLOGY | $2,715 |
| Takeda Pharmaceuticals U.S.A., Inc. Feb 5, 2025 | Consulting Fee | $2,600 |
| Takeda Pharmaceuticals U.S.A., Inc. Jan 28, 2025 | Travel and Lodging travel to CAMBRIDGE, MA · in-kind | $419 |
| Pfizer Inc. Jan 21, 2025 | Consulting Fee | $3,000 |
| Leo Pharma Inc. Jan 16, 2025 | Consulting Fee | $3,620 |
| Leo Pharma Inc. Jan 16, 2025 | Travel and Lodging travel to CHESHIRE, CT | $736 |
| Regeneron Healthcare Solutions, Inc. Jan 10, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $1,670 |
| UCB, Inc. Jan 7, 2025 | Consulting Fee Bimzelx · Immunology | $2,250 |
| UCB, Inc. Jan 3, 2025 | Travel and Lodging Bimzelx · Immunology · travel to AURORA, CO · in-kind | $299 |
| UCB, Inc. Jan 3, 2025 | Travel and Lodging Bimzelx · Immunology · travel to AURORA, CO · in-kind | $293 |
| UCB, Inc. Jan 3, 2025 | Travel and Lodging Bimzelx · Immunology · travel to AURORA, CO · in-kind | $58.74 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $175,207 in research payments for these studies, mostly to the institutions running them.
- A Study of DS-7011a in Patients With Systemic Lupus Erythematosus
Daiichi Sankyo Inc. · Completed · NCT05638802 - TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis
Takeda Pharmaceuticals U.S.A., Inc. - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
AbbVie Inc. · Active, not recruiting · NCT06389136 - A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color
Eli Lilly and Company · Completed · NCT05372419 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up)
AbbVie Inc. - A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
AbbVie Inc. · Completed · NCT05601882
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.